AUS
NZ
UK
CA
USA
IND
Highlights
- Uniphar PLC (LSE:UPR) is a global partner to pharma and medtech manufacturers.
- The firm is on track to fulfill the strategic mission of doubling 2018 proforma EBITDA in a span of 5 years of going public.
- UPR's revenue increased by 6.6% while there was 17% YoY growth in its operating profit during FY22.
FTSE AIM 100 index listed Uniphar PLC (LSE:UPR) is a global partner to pharma and medtech manufacturers. It is currently catering to the demand of over 200 multinational pharmaceutical and medical technology. The company is focusing in making its market leadership position stronger in Supply Chain and Retail division. The firm is on track to fulfill the strategic mission of doubling 2018 proforma EBITDA in a span of 5 years of going public. There has been approximately 4.8% year-on-year surge in annual dividend payments for the fiscal year 2022.
Uniphar has acquired Orspec and BModesto under its division of Product Access to widen its footprint in the APAC region and continental Europe.
Despite continued macro-economic uncertainty and inflationary pressure, UPR's revenue increased by 6.6% while there was 17% YoY growth in its operating profit during FY22. Its Adjusted EPS registered a 13.2% YoY jump to 18.4 euro cents. The company paid a final dividend of 1.13 euro cents per share in May this year.
Outlook
Out of the four value accretive acquisitions targeted for FY22, UPR has completed three acquisitions in FY22, while the last one, McCauley Pharmacy Group, was acquired in January 2023. Also, the firm has made huge investment in a new distribution facility following the company’s growth strategy.
Top 10 shareholders
Around 41.03% of the UPR’s total shareholdings are owned by its top ten shareholders. While Allianz Global Investors GmbH owns over 10% shareholding, Polar Capital LLP holds approximately 7.37% shareholding.
Stock Price Performance
UPR’s stock price has dropped by approximately 6.27% in the last one month. It has fallen by over 20.33% in the last six months. The stock’s 52-week low and high price stands at GBX 223.27 and GBX 344.00, respectively.
Please note markets are trading in a highly volatile zone currently due to certain macro-economic and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 30 August 2023. The reference data in this report has been partly sourced from EODHD/Others.
